Haro Hartounian Ph.D., executive director, bio-pharmaceutical cluster development at the New Jersey Innovation Institute will moderate an industry panel focused on The View Ahead at the Regional Pharma Manufacturing Expo, November 17, 2016 at the DoubleTree Hotel, Somerset, NJ. Panelists will include David Pollard, Ph.D., executive director of bioprocess technology & expression, bioprocess development, Merck; Joanne T. Beck, Ph.D. executive vice president, global pharmaceutical development & operations, Celgene and Ben Locwin, Ph.D., president, Healthcare Science Advisors.
While addressing unmet medical needs, pharmaceutical and biotech companies are facing a complex and challenging future. Technological advances in pharmaceutical and biologics manufacturing are stimulating new processes and opening new opportunities.
RPM Expo is a marketplace for manufacturing engineers, managers, and front line operators to meet with innovative and mature service companies. In addition to manufacturing equipment makers, RPM Expo 2016 will bring together decision makers with the resources required to implement evolving solutions in this highly regulated environment. The Expo is focused on today’s most advanced strategies and technologies for manufacturing drugs reproducibly and cost-effectively.
In addition to his role as executive director for the biopharmaceutical iLab at NJII, Dr. Hartounian is an adjunct associate professor at Columbia’ University’s Chemical Engineering Department. He was formerly the CEO and Co-Founder of DIAVACS, a clinical-stage biotechnology company whose mission is to treat auto-immune diseases, and he founded Allied Bioventures, a business advisory service working with companies in the life sciences industry.
Dr. Hartounian also serves as QED Advisor for member companies in the University City Science Center. And he served as President and CEO of Vyteris, Inc. He was founder, director and CEO of Protagenic Therapeutics Inc., a biotechnology company created to develop treatments for neurological disorders. Dr. Hartounian was also president and COO of Microislet, Inc., where he established Microislet as a major player in the field of cell therapy for treatment of Type 1 diabetes.